What is not working for the company?
What is working for the company?
|Name||Sep 22||Jun 22|
|Mutual Funds (Change:0.00)||0%||0%|
|Insurance Companies (Change:0.00)||0%||0%|
|Other DIIs (Change:0.00)||0.44%||0.44%|
|Non Institution (Change:0.00)||35.69%||35.69%|
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in DAI-ICHI KARKARIA LTD.
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
Frequently Asked Questions
What is the Share price of DAI-ICHI KARKARIA LTD. (DAICHI)?
Can I buy DAI-ICHI KARKARIA LTD. (DAICHI) shares?
How do I buy DAI-ICHI KARKARIA LTD. (DAICHI) from Angel One?
- Direct investment: You can buy DAI-ICHI KARKARIA LTD. (DAICHI) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to DAI-ICHI KARKARIA LTD. (DAICHI) shares.
In which sector do DAI-ICHI KARKARIA LTD. (DAICHI) belong?
Today's live share price for DAI-ICHI KARKARIA LTD. is NSE: N/A, BSE: ₹ 392.05 with a current market capitalization of .
Dai Ichi Karkaria (DIK), manufactures speciality chemicals has a tie-up with Matsumoto to manufacture spin finishes, which are used for imparting lubrication and anti-static properties to textile filaments and yarns. It is now expanding its production capacity from 750 tpa to 3000 tpa. DIK had set up a unit to manufacture certain bulk drugs omeprazole, menadione and calcium pentothenate, the last two will be manufactured in India for the first time. DIK is also setting up a unit to manufacture 600 tpa of polyacrylamide-based flocculents which are used for solid-liquid separation. The expansion cum Diversification plan for High Molecular Weight Flocculants Project at Kurkumbh has been successfully completed. Company had joint venture with project consultant for effluent treatment plants for increasing business. Company Bulk Drugs & Fine Chemical Projects for patented molecule processes were developed and were scaled up to commercial level by March-99. Company plans to start development of three new products in the pilot facility which is being upgraded presently to meet strict cGMP condition. Company also negotiating with foreign customer for product specific tie-ups in future. Company Spin fishes continue to do well & POY DTY finish has been accepted in the market & company hopes to get orders from leading synthetic fibre manufacturers. During the year 1999-2000, the company's successfully introduced eight new products in therapeutic areas of cardiovascular, antihistaminics, analgesics, anxiolytic, antidepressant and anticonsulgants. The diversification programme which was taken up by the company is focusing in the three major areas are ETP,paper and Alumina industry.Read more